The PCA 3 assay has recently been shown to be of benefit in guiding initial prostate biopsy decisions, and has also been externally validated into risk nomograms which can be used to assist clinicians with risk stratification when a decision to biopsy is being contemplated. In view of the above, I am firstly writing to commend Ochiai et al. for
a concise review on the first study which assessed the PCA3 assay in a Japanese setting. Their report has been received with great interest in our region.